Myeloma SPORE

The Dana-Farber/Harvard SPORE in multiple myeloma (Myeloma SPORE) is an key component of the DF/HCC program to find new treatments for multiple myeloma. This cancer of the blood-forming tissues affects 14,000 new individuals in the United States each year, with 50,000 total patients, and remains incurable despite conventional and high-dose therapies. Among the five collaborative projects underway is an effort to identify the genes involved and develop appropriate target drugs to prevent or delay disease progression. The Myeloma SPORE represents a significant collaboration that includes research investigators from all of the major DF/HCC sites.

Project 1: Proteasome – Directed Novel Myeloma Therapies

Project 2: Targeting Telomere Expansion Mechanisms

Project 3: MUC1 as Therapeutic Target in Multiple Myeloma

Project 4: Novel Therapeutics Targeting Genetic Abnormalities in Multiple Myeloma

Project 5: Cytogenetic and Molecular Correlates of Evolution from MGUS to Multiple Myeloma